News >

EU Panel Backs Expanded Indication of Ibrutinib Combos in CLL and Waldenstrom Macroglobulinemia

Gina Columbus @ginacolumbusonc
Published: Friday, Jun 28, 2019

Alessandra Tedeschi MD

Alessandra Tedeschi MD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indications of ibrutinib (Imbruvica) to include use in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia (CLL), and also in combination with rituximab (Rituxan) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication